Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment

被引：0

作者：

Salimbeni, Beatrice Taurelli ^{[1
]}

Giudici, Fabiola ^{[2
]}

Pescia, Carlo ^{[3
,4
]}

Giachetti, Pier Paolo Maria Berton ^{[1
,5
]}

Scafetta, Roberta ^{[1
,6
]}

Zagami, Paola ^{[1
,5
]}

Marra, Antonio ^{[1
,5
]}

Trapani, Dario ^{[1
,5
]}

Esposito, Angela ^{[1
]}

Scagnoli, Simone ^{[7
]}

Cerbelli, Bruna ^{[8
]}

Botticelli, Andrea ^{[7
]}

Munzone, Elisabetta ^{[9
]}

Fusco, Nicola ^{[3
,5
]}

Criscitiello, Carmen ^{[1
,5
]}

Curigliano, Giuseppe ^{[1
,5
]}

机构：

[1] European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev Innovat Therapies, Milan, Italy

[2] Ctr Riferimento Oncol Aviano CRO IRCCS, Canc Epidemiol Unit, Aviano, Italy

[3] European Inst Oncol IRCCS, Div Pathol, Milan, Italy

[4] ASST Santi Paolo & Carlo, Div Pathol, Milan, Italy

[5] Univ Milan, Dept Oncol & Haemato Oncol, Milan, Italy

[6] Campus Biomed Univ Rome, Med Oncol Dept, Rome, Italy

[7] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy

[8] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Rome, Italy

[9] European Inst Oncol IRCCS, Div Med Senol, Milan, Italy

来源：

NPJ BREAST CANCER | 2025年 / 11卷 / 01期

关键词：

TRASTUZUMAB EMTANSINE; SURVIVAL; PERTUZUMAB; DOCETAXEL; ANTIBODY; PLACEBO; RELAPSE; PLUS;

D O I：

10.1038/s41523-025-00760-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer (BC) is a leading cause of death among women, with approximately 30% HER2-positive (HER2+). Although HER2-targeted therapies have improved outcomes for patients with HER2+ metastatic breast cancer (mBC), clinical challenges and prognostic variability remain. Tumor-infiltrating lymphocytes (TILs) have emerged as prognostic and predictive biomarkers in various tumors, including BC, but their role in HER2+ mBC is poorly understood. This multicentric retrospective cohort study evaluated the prognostic significance of TILs in 110 patients with HER2+ mBC treated with pertuzumab, trastuzumab, and taxane-based chemotherapy at two Italian institutes from June 2013 to May 2024. TILs were assessed on metastatic or primary tumor samples. High TILs levels (>5%) were independently associated with longer PFS and OS. TILs levels were higher in primary tumours than in metastases (p = 0.009), with significant variation by metastatic site. These findings underscore the potential of TILs as prognostic biomarkers in HER2+ mBC, necessitating further prospective studies.

引用

页数：12

共 37 条

[1] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].

Allison, Kimberly H. ;

Hammond, M. Elizabeth H. ;

Dowsett, Mitchell ;

McKernin, Shannon E. ;

Carey, Lisa A. ;

Fitzgibbons, Patrick L. ;

Hayes, Daniel F. ;

Lakhani, Sunil R. ;

Chavez-MacGregor, Mariana ;

Perlmutter, Jane ;

Perou, Charles M. ;

Regan, Meredith M. ;

Rimm, David L. ;

Symmans, W. Fraser ;

Torlakovic, Emina E. ;

Varella, Leticia ;

Viale, Giuseppe ;

Weisberg, Tracey F. ;

McShane, Lisa M. ;

Wolff, Antonio C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+

[2] Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens [J].

Baine, Marina K. ;

Turcu, Gabriela ;

Zito, Christopher R. ;

Adeniran, Adebowale J. ;

Camp, Robert L. ;

Chen, Lieping ;

Kluger, Harriet M. ;

Jilaveanu, Lucia B. .

ONCOTARGET, 2015, 6 (28) :24990-25002

[3] The immune system and response to HER2-targeted treatment in breast cancer [J].

Bianchini, Giampaolo ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (02) :E58-E68

[4] Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study [J].

Cimino-Mathews, Ashley ;

Ye, Xiaobu ;

Meeker, Alan ;

Argani, Pedram ;

Emens, Leisha A. .

HUMAN PATHOLOGY, 2013, 44 (10) :2055-2063

[5] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer [J].

Cortes, J. ;

Kim, S. -B ;

Chung, W. -P ;

Im, S. -A ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L. -M ;

Petry, V ;

Chung, C. -F ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Huang, C. -S ;

Kim, J. H. ;

Chiu, J. W. Y. ;

Pedrini, J. L. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) :1143-1154

[6] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer [J].

Criscitiello, C. ;

Vingiani, A. ;

Maisonneuve, P. ;

Viale, G. ;

Vialel, G. ;

Curigliano, G. .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) :347-354

[7] Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J].

Denkert, Carsten ;

von Minckwitz, Gunter ;

Darb-Esfahani, Silvia ;

Lederer, Bianca ;

Heppner, Barbara I. ;

Weber, Karsten E. ;

Budczies, Jan ;

Huober, Jens ;

Klauschen, Frederick ;

Furlanetto, Jenny ;

Schmitt, Wolfgang D. ;

Blohmer, Jens-Uwe ;

Karn, Thomas ;

Pfitzner, Berit M. ;

Kuemmel, Sherko ;

Engels, Knut ;

Schneeweiss, Andreas ;

Hartmann, Arndt ;

Noske, Aurelia ;

Fasching, Peter A. ;

Jackisch, Christian ;

van Mackelenbergh, Marion ;

Sinn, Peter ;

Schem, Christian ;

Hanusch, Claus ;

Untch, Michael ;

Loibl, Sibylle .

LANCET ONCOLOGY, 2018, 19 (01) :40-50

[8] Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+breast cancer [J].

Dieci, M. V. ;

Conte, P. ;

Bisagni, G. ;

Brandes, A. A. ;

Frassoldati, A. ;

Cavanna, L. ;

Musolino, A. ;

Giotta, F. ;

Rimanti, A. ;

Garrone, O. ;

Bertone, E. ;

Cagossi, K. ;

Sarti, S. ;

Ferro, A. ;

Piacentini, F. ;

Maiorana, A. ;

Orvieto, E. ;

Sanders, M. ;

Miglietta, F. ;

Balduzzi, S. ;

D'Amico, R. ;

Guarneri, V. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :418-423

[9] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study [J].

Dirix, Luc Y. ;

Takacs, Istvan ;

Jerusalem, Guy ;

Nikolinakos, Petros ;

Arkenau, Hendrik-Tobias ;

Forero-Torres, Andres ;

Boccia, Ralph ;

Lippman, Marc E. ;

Somer, Robert ;

Smakal, Martin ;

Emens, Leisha A. ;

Hrinczenko, Borys ;

Edenfield, William ;

Gurtler, Jayne ;

von Heydebreck, Anja ;

Grote, Hans Juergen ;

Chin, Kevin ;

Hamilton, Erika P. .

BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) :671-686

[10]

Emens LA, 2020, LANCET ONCOL, V21, P1283, DOI 10.1016/S1470-2045(20)30465-4

← 1 2 3 4 →